Arizona Cancer Therapeutics, LLC, is an early-stage biopharmaceutical company developing targeted peptide-based therapies for the treatment of breast cancer. The firm develops novel, non-toxic treatment alternatives to existing therapies that have limited efficacy and unwanted side-effects for the treatment of metastatic breast cancer. The company's lead therapeutic, PMIP (Protein Transduction Domain 4, MUC1 Inhibitory Peptide), is designed to block the interaction of two proteins in cells that cause breast cancer to grow and spread through nhibiting cancer-specific molecular interactions with low patient toxicity. The company's peptide therapies target oncogenic pathways that are commonly upregulated in the most aggressive subtypes of breast cancer. The firm's two co-founders are staff at the University of Arizona and have strong ties with the University.
